デュシェンヌ型筋ジストロフィー（DMD）治療薬の世界市場レポート 2024年

デュシェンヌ型筋ジストロフィー（DMD）治療薬の市場規模は近年急激に拡大しています。2023年の86億4,000万米ドルから2024年には119億5,000万米ドルに、CAGR38.4％で拡大します。歴史的な期間の成長は、デュシェンヌ型筋ジストロフィーの有病率の増加、デュシェンヌ型筋ジストロフィー治療に関する認知度、ヘルスケア支出の増加、政府の取り組みに起因しています。

遺伝性疾患の増加は、今後数年間におけるデュシェンヌ型筋ジストロフィー（DMD）市場の成長を促進する見通しです。遺伝子疾患には、個人のDNAや遺伝物質の異常や変異に起因するさまざまな病状が含まれます。遺伝性疾患の有病率が上昇を続ける中、遺伝子変異や家族性の遺伝的素因によりDMDに罹患する人口が増加しています。その結果、この増加傾向により、DMD関連の診断、動向、治療ソリューションに対する需要が高まると予想されます。例えば、2021年、米国を拠点とする政府機関である疾病対策予防センター（CDC）は、先天性欠損症が毎年米国で生まれる全出生児の約3％、合計33人に1人に影響を及ぼすと報告しました。さらに、これらの欠陥は乳幼児死亡の主な原因であり、全乳幼児死亡の20％を占めています。このように、遺伝性疾患の有病率の増加は、デュシェンヌ型筋ジストロフィー（DMD）市場の拡大を推進する重要な要因となっています。

2023年のDMD治療薬市場では北米が最大地域でした。デュシェンヌ型筋ジストロフィー（DMD）治療薬レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界のデュシェンヌ型筋ジストロフィー（DMD）治療薬市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 低分子
• 生物製剤
• 世界のデュシェンヌ型筋ジストロフィー（DMD）治療薬市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• オフライン
• オンライン
• 世界のデュシェンヌ型筋ジストロフィー（DMD）治療薬市場、アプリケーション別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• クリニック
• 在宅ケア

第7章 地域および国の分析

• 世界のデュシェンヌ型筋ジストロフィー（DMD）治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界のデュシェンヌ型筋ジストロフィー（DMD）治療薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• デュシェンヌ型筋ジストロフィー（DMD）治療薬市場の競合情勢
• デュシェンヌ型筋ジストロフィー（DMD）治療薬市場の企業プロファイル
  • CVS Health Corporation
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Co.

第31章 その他の主要および革新的な企業

• Otsuka Holdings Co. Ltd.
• Daiichi Sankyo Co. Ltd.
• BioMarin Pharmaceutical Inc.
• Nippon Shinyaku Co. Ltd.
• CRISPR Therapeutics AG
• Sarepta Therapeutics Inc.
• PTC Therapeutics Inc.
• Halozyme Therapeutics Inc.
• FibroGen, Inc.
• Exonics Therapeutics Inc.
• Italfarmaco S.p.A.
• Wave Life Sciences Ltd.
• MeiraGTx Holdings plc
• Editas Medicine Inc.
• NS Pharma Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

“Duchenne Muscular Dystrophy (DMD) Therapeutics Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on duchenne muscular dystrophy (dmd) therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for duchenne muscular dystrophy (dmd) therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The duchenne muscular dystrophy (dmd) therapeutics market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Type: Small Molecules; Biologics
• 2) By Distribution Channel: Offline; Online
• 3) By Application: Hospitals; Clinics; Home Care
• Companies Mentioned: CVS Health Corporation; Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Bristol-Myers Squibb Company; Eli Lilly and Co.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Duchenne muscular dystrophy (DMD) therapeutics encompass a range of medical interventions and treatments devised to address and mitigate the symptoms associated with DMD, a genetic ailment characterized by progressive muscle weakening and deterioration. The primary objective of these therapeutic strategies is to retard the advancement of the disease, enhance muscle function, and augment the overall well-being of individuals afflicted by Duchenne muscular dystrophy.

The principal categories of DMD therapeutics consist of small molecules and biologics. Small molecules are compounds with low molecular weight that can specifically interact with certain proteins or targets within the body. These can be tailored to address various facets of DMD, such as mitigating inflammation, fostering muscle regeneration, or targeting specific genetic mutations. The distribution of these therapeutics occurs through both offline and online channels, catering to applications in hospitals, clinics, and home care settings.

The duchenne muscular dystrophy (DMD) therapeutics market research report is one of a series of new reports from The Business Research Company that provides duchenne muscular dystrophy (DMD) therapeutics market statistics, including duchenne muscular dystrophy (DMD) therapeutics industry global market size, regional shares, competitors with a duchenne muscular dystrophy (DMD) therapeutics market share, detailed duchenne muscular dystrophy (DMD) therapeutics market segments, market trends and opportunities and any further data you may need to thrive in the duchenne muscular dystrophy (DMD) therapeutics industry. This duchenne muscular dystrophy (DMD) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The duchenne muscular dystrophy (dmd) therapeutics market size has grown exponentially in recent years. It will grow from $8.64 billion in 2023 to $11.95 billion in 2024 at a compound annual growth rate (CAGR) of 38.4%. The growth in the historic period can be attributed to increasing prevalence of duchenne muscular dystrophy, awareness about duchenne muscular dystrophy treatment, rising healthcare spending, government initiatives.

The duchenne muscular dystrophy (dmd) therapeutics market size is expected to see exponential growth in the next few years. It will grow to $36.72 billion in 2028 at a compound annual growth rate (CAGR) of 32.4%. The growth in the forecast period can be attributed to growing investments in for duchenne muscular dystrophy treatments, adoption of combination therapies, emergence of biomarker,growing number of screening programs for duchenne muscular dystrophy. Major trends in the forecast period include innovative treatments for duchenne muscular dystrophy, development of targeted therapies, introduction of novel medications and therapies, innovative disease-modifying therapies, active drug developments.

The growth of the Duchenne muscular dystrophy (DMD) therapeutics market is anticipated to be propelled by the increasing number of clinical trials. Clinical trials represent essential research studies involving human participants aimed at assessing the safety, efficacy, and potential advantages of new medical treatments, interventions, or medications. The upsurge in clinical trials dedicated to exploring Duchenne muscular dystrophy treatments underscores the ongoing commitment to research, innovation, and a diverse range of therapeutic possibilities. This trend is poised to result in improved patient outcomes, heightened investments, and the accelerated development and accessibility of effective DMD therapies. For example, in August 2023, as reported by Clinicaltrials.gov, a branch of the National Institutes of Health (NIH), the number of registered clinical trials has increased to 464,218, marking a significant rise from 399,496 in 2021. These trials are conducted across all 50 states of the United States and in 221 countries. Additionally, 31% of these studies, totaling 142,700, are registered within the U.S., while the remaining 53% of studies (248,310) are documented in international locations. Consequently, the escalating count of clinical trials is expected to be a driving force behind the expansion of the Duchenne muscular dystrophy (DMD) therapeutics market.

The increasing occurrence of genetic disorders is poised to fuel the growth of the Duchenne muscular dystrophy (DMD) market in the years to come. Genetic disorders encompass a range of medical conditions stemming from abnormalities or mutations in an individual's DNA or genetic material. As the prevalence of genetic disorders continues to rise, a larger segment of the population becomes susceptible to DMD due to genetic mutations or familial genetic predispositions. Consequently, this upward trend is expected to drive greater demand for DMD-related diagnostics, treatments, and therapeutic solutions. For instance, in 2021, the Centers for Disease Control and Prevention (CDC), a U.S.-based government agency, reported that birth defects affect approximately 3% of all babies born in the United States each year, totaling one in every 33 babies. Furthermore, these defects are the primary cause of infant mortality, accounting for 20% of all infant deaths. Thus, the increasing prevalence of genetic disorders is a key factor propelling the expansion of the Duchenne muscular dystrophy (DMD) market.

The high cost of treatment can potentially limit access to care and may act as a restraining factor for the growth of the Duchenne muscular dystrophy (DMD) therapeutics market during the projected period. The elevated cost of therapeutics for Duchenne muscular dystrophy (DMD) presents a substantial obstacle for patients. It can lead to reduced demand for treatment, delays in both diagnosis and therapy, financial strain on patients, restricted access to healthcare, constrained market expansion, increased healthcare expenditures, and an overall reduction in the quality of life. For example, as of February 2023, the Institute for Clinical and Economic Review (ICER), a U.S.-based non-profit organization, reported that the average cost of a gene therapy dose falls in the range of $1 million to $2 million. Thus, the high cost of treatment poses a hindrance to the growth of the Duchenne muscular dystrophy (DMD) therapeutics market.

The leading companies in the field of Duchenne muscular dystrophy (DMD) therapeutics are embracing innovative technologies to enhance the effectiveness and accessibility of treatments for DMD patients while maintaining their competitive edge in the market. A case in point is Bit Bio Ltd., a UK-based synthetic biology company, which, in July 2023, introduced disease model products aimed at advancing Duchenne muscular dystrophy (DMD) treatments. These disease models, specifically the ioSkeletal Myocytes DMD Exon 44 Deletion and ioSkeletal Myocytes DMD Exon 52 Deletion, consist of human skeletal myocytes engineered to carry deletions in the gene responsible for dystrophin protein production. Derived from induced pluripotent stem cells (iPSCs), Bit Bio's models offer a reliable and scalable source of human cells for research, addressing challenges associated with variability and the sourcing of primary cells. These models provide valuable insights into disease mechanisms and potential therapies, supporting the development of treatments for DMD. This technological advancement has the potential to expedite the work of researchers striving to find effective solutions for Duchenne muscular dystrophy.

In December 2022, Solid Biosciences Inc., a biotechnology firm headquartered in the United States, successfully completed the acquisition of AavantiBio, Inc. The financial details of the transaction remain undisclosed. This acquisition represents a significant move by Solid Biosciences to extend its collection of gene therapy programs, focusing on neuromuscular and cardiac diseases. The incorporation of AavantiBio, Inc. has not only broadened the company's capabilities but also brought in valuable expertise and financial resources for advancing research and development efforts and reaching potential milestones. AavantiBio, Inc., a gene therapy company based in the United States, specializes in the development of groundbreaking treatments for Duchenne muscular dystrophy and various other neuromuscular and cardiac diseases.

Major players in the duchenne muscular dystrophy (dmd) therapeutics market are CVS Health Corporation, Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Eli Lilly and Co., Otsuka Holdings Co. Ltd., Daiichi Sankyo Co. Ltd., BioMarin Pharmaceutical Inc., Nippon Shinyaku Co. Ltd., CRISPR Therapeutics AG, Sarepta Therapeutics Inc., PTC Therapeutics Inc., Halozyme Therapeutics Inc., FibroGen Inc., Exonics Therapeutics Inc., Italfarmaco S.p.A., Wave Life Sciences Ltd., MeiraGTx Holdings plc, Editas Medicine Inc., NS Pharma Inc., Solid Biosciences Inc., Santhera Pharmaceuticals Holding, Avidity Biosciences LLC, ReveraGen BioPharma Inc., Capricor Therapeutics Inc., Dynacure S.A., Summit Therapeutics plc.

North America was the largest region in the DMD therapeutics market in 2023. The regions covered in duchenne muscular dystrophy (DMD) therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the duchenne muscular dystrophy (DMD) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The duchenne muscular dystrophy (DMD) therapeutics market includes revenues earned by entities by providing services including gene therapies, genetic testing and counseling, telehealth and remote monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The duchenne muscular dystrophy (DMD) therapeutics market also include sales of casimersen, eteplirsen and golodirsen. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Characteristics

3. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends And Strategies

4. Duchenne Muscular Dystrophy (DMD) Therapeutics Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth

• 5.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segmentation

• 6.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Small Molecules
• Biologics
• 6.2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Offline
• Online
• 6.3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Clinics
• Home Care

7. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Regional And Country Analysis

• 7.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 8.1. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 9.1. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• 9.2. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 10.1. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 11.1. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• 11.2. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 12.1. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 13.1. Indonesia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 14.1. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• 14.2. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 15.1. Western Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• 15.2. Western Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 16.1. UK Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 17.1. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 18.1. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 19.1. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 20.1. Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 21.1. Eastern Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• 21.2. Eastern Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 22.1. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 23.1. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• 23.2. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 24.1. USA Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• 24.2. USA Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 25.1. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• 25.2. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 26.1. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• 26.2. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 27.1. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 28.1. Middle East Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• 28.2. Middle East Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market

• 29.1. Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
• 29.2. Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market, Segmentation By Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Competitive Landscape
• 30.2. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Company Profiles
  • 30.2.1. CVS Health Corporation
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Pfizer Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. F. Hoffmann-La Roche Ltd.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Bristol-Myers Squibb Company
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Eli Lilly and Co.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Other Major And Innovative Companies

• 31.1. Otsuka Holdings Co. Ltd.
• 31.2. Daiichi Sankyo Co. Ltd.
• 31.3. BioMarin Pharmaceutical Inc.
• 31.4. Nippon Shinyaku Co. Ltd.
• 31.5. CRISPR Therapeutics AG
• 31.6. Sarepta Therapeutics Inc.
• 31.7. PTC Therapeutics Inc.
• 31.8. Halozyme Therapeutics Inc.
• 31.9. FibroGen, Inc.
• 31.10. Exonics Therapeutics Inc.
• 31.11. Italfarmaco S.p.A.
• 31.12. Wave Life Sciences Ltd.
• 31.13. MeiraGTx Holdings plc
• 31.14. Editas Medicine Inc.
• 31.15. NS Pharma Inc.

32. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Competitive Benchmarking

33. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Duchenne Muscular Dystrophy (DMD) Therapeutics Market

35. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Future Outlook and Potential Analysis

• 35.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer